Raymond James & Associates Eli Lilly & CO Put Options Transaction History

Raymond James & Associates

4 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Oct 18, 2024	BUY	$772.14 - $960.02 $231,642 - $288,006	300 New	300 $265,000
Q2 2023 Jul 25, 2023	SELL	$350.74 - $468.98 $1.93 Million - $2.58 Million	-5,500 Reduced 50.0%	5,500 $2.58 Million
Q1 2023 Apr 14, 2023	BUY	$310.63 - $364.82 $1.71 Million - $2.01 Million	5,500 Added 100.0%	11,000 $3.78 Million
Q4 2022 Feb 08, 2023	BUY	$321.55 - $374.67 $1.77 Million - $2.06 Million	5,500 New	5,500 $2.01 Million

4,003

752M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $716B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.